Your shopping cart is currently empty

(R)-LW-Srci-8 is a selective covalent inhibitor of c-Src, with an IC50 of 35.83 nM, that disrupts c-Src autophosphorylation by targeting the autophosphorylation site (Y419) of the c-Src kinase.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | (R)-LW-Srci-8 is a selective covalent inhibitor of c-Src, with an IC50 of 35.83 nM, that disrupts c-Src autophosphorylation by targeting the autophosphorylation site (Y419) of the c-Src kinase. |
| In vitro | MDA-MB-468 (5-20 μM; 3 h) inhibits the phosphorylation of c-Src at Y419 and STAT3 at Y705 in MDA-MB-468 cells in a dose-dependent manner. |
| Formula | C19H22F2N2O2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.